Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks.
Yuge WangXiaonan ZhongHonghao WangYu PengFudong ShiDongmei JiaHuan YangQiuming ZengChao QuanJingzi ZhangBaoMichael LeeJun QiXiaoxiang ChenWei Qiunull nullPublished in: European journal of neurology (2022)
Batoclimab add-on therapy to IVMP is safe and tolerated in patients with NMOSD. Preliminary evidence suggests a beneficial neurological effect. A randomized controlled trial would be needed to prove the efficacy.